Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients
dc.contributor.author | Veit, Olivia | |
dc.contributor.author | Niedrig, Matthias | |
dc.contributor.author | Chapuis‐Taillard, Caroline | |
dc.contributor.author | Cavassini, Matthias | |
dc.contributor.author | Mossdorf, Erik | |
dc.contributor.author | Schmid, Patrick | |
dc.contributor.author | Bae, Hi‐Gung | |
dc.contributor.author | Litzba, Nadine | |
dc.contributor.author | Staub, Thomas | |
dc.contributor.author | Hatz, Christoph | |
dc.contributor.author | Furrer, Hansjakob | |
dc.date.accessioned | 2018-05-07T13:54:56Z | |
dc.date.available | 2018-05-07T13:54:56Z | |
dc.date.created | 2010-06-01 | |
dc.date.issued | 2009-03-01 | none |
dc.identifier.other | http://edoc.rki.de/oa/articles/retwdjnw9zjA/PDF/26uxVOJaCw4P6.pdf | |
dc.identifier.uri | http://edoc.rki.de/176904/652 | |
dc.description.abstract | Background: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)–infected patients, and adequate immunogenicity and safety are of concern in this population. Methods: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:10 were defined as reactive, and those of 1: | eng |
dc.language.iso | eng | |
dc.publisher | Robert Koch-Institut | |
dc.subject | Adult | eng |
dc.subject | Humans | eng |
dc.subject | Female | eng |
dc.subject | Male | eng |
dc.subject | RNA | eng |
dc.subject | Antibodies | eng |
dc.subject | Viral/blood | eng |
dc.subject | Cohort Studies | eng |
dc.subject | Neutralization Tests | eng |
dc.subject | Viral Load | eng |
dc.subject | CD4 Lymphocyte Count | eng |
dc.subject | HIV Infections/immunology | eng |
dc.subject | Plaque Assay | eng |
dc.subject | Switzerland | eng |
dc.subject | Yellow Fever/immunology | eng |
dc.subject | Yellow Fever/prevention & control | eng |
dc.subject | Yellow Fever Vaccine/adverse effects | eng |
dc.subject | Yellow Fever Vaccine/immunology | eng |
dc.subject.ddc | 610 Medizin | |
dc.title | Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients | |
dc.type | periodicalPart | |
dc.identifier.urn | urn:nbn:de:0257-1008892 | |
dc.identifier.doi | 10.1086/597006 | |
dc.identifier.doi | http://dx.doi.org/10.25646/577 | |
local.edoc.container-title | Clinical Infectious Diseases | |
local.edoc.fp-subtype | Artikel | |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-url | http://www.journals.uchicago.edu/doi/abs/10.1086/597006 | |
local.edoc.container-publisher-name | University of Chicago Press | |
local.edoc.container-volume | 48 | |
local.edoc.container-year | 2009 |